A Phase I Trial of Post-Transplant Bortezomib and High Dose Cyclophosphamide as Graft-Versus-Host Disease (GVHD) Prophylaxis After Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT)
Latest Information Update: 02 Jan 2023
At a glance
- Drugs Bortezomib (Primary) ; Cyclophosphamide
- Indications Graft-versus-host disease
- Focus Adverse reactions
- 22 Nov 2022 Status changed from active, no longer recruiting to completed.
- 25 Mar 2016 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
- 20 Nov 2015 Planned primary completion date changed from 1 Aug 2015 to 1 May 2016 as per ClinicalTrials.gov record.